The nation of Zimbabwe has turned down a substantial US health deal valued at 367 million US dollars (272 million pounds) over five years because of Washington's demand for sensitive biological samples.
The decision became public following a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesperson later clarified that the United States was demanding access to biological samples for scientific study and commercial purposes while was unwilling to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged continued talks to reach a agreement acceptable to all parties so the nation's critical HIV treatment initiative can proceed.
Wider Context
This rejection comes after a comparable situation in Kenya, where a high court halted a similar deal with the US following concerns were filed about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and accountability.
As per statements, 16 African countries have so far signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that shared data," he stated.
"In essence, our country would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our people if a future pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were undermining systems already established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This framework is designed to ensure that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued dialogue with our US partners on how subsequent collaboration could be designed in a manner that respects the sovereignty and interests of both nations."
Medical Community Response
Medical experts expressed it understood the government's concerns, but suggested that negotiations need to persist considering much of the country's HIV programmes were funded by external financing.
"If specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
This impasse emphasises the continuing challenges between receiving vital international aid and protecting national sovereignty in an ever more data-driven world.